Compare FN & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FN | ARWR |
|---|---|---|
| Founded | 1999 | 2003 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.6B | 12.4B |
| IPO Year | 2007 | 2009 |
| Metric | FN | ARWR |
|---|---|---|
| Price | $455.21 | $60.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 14 |
| Target Price | ★ $734.11 | $107.23 |
| AVG Volume (30 Days) | 779.7K | ★ 2.1M |
| Earning Date | 11-02-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 42.31 | ★ 99.80 |
| EPS | ★ 13.05 | N/A |
| Revenue | ★ $4,641,097,000.00 | $16,142,321.00 |
| Revenue This Year | $31.50 | N/A |
| Revenue Next Year | $19.73 | N/A |
| P/E Ratio | $37.33 | ★ N/A |
| Revenue Growth | ★ 35.73 | N/A |
| 52 Week Low | $366.49 | $34.61 |
| 52 Week High | $748.89 | $95.49 |
| Indicator | FN | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 52.76 | 29.60 |
| Support Level | $449.04 | $54.02 |
| Resistance Level | $501.69 | $66.37 |
| Average True Range (ATR) | 22.67 | 2.27 |
| MACD | 8.04 | 0.08 |
| Stochastic Oscillator | 51.11 | 10.95 |
Fabrinet provides advance-level optical packaging and precision optical, electro-mechanical, and electronic manufacturing services to original equipment manufacturers of complex products, such as optical communication components, modules and sub-systems, industrial lasers, automotive components, medical devices, and sensors. The company offers a broad range of advance optical and electro-mechanical capabilities across the entire manufacturing process, including process design and engineering, supply chain management, manufacturing, complex printed circuit board assembly, advance-level of packaging, integration, final assembly, and testing. The company generates the majority of its revenue from North America and Asia-Pacific, with the rest from Europe.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.